NeuroSense Therapeutics Ltd.’s stock rose 6.5% Tuesday, as analysts cheered data from the biotech’s late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
More Stories
AstraZeneca to pay up to $2 billion to license cardiovascular drug
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
Arcadium Lithium stock soars as report of Rio Tinto acquisition bid is confirmed
Global mining giant Rio Tinto PLC has expressed interest in buying Arcadium Lithium PLC, both companies confirmed Sunday.
Starboard reportedly takes $1 billion stake in Pfizer, seeks changes
Activist investor Starboard Value has taken a $1 billion stake in beleaguered drugmaker Pfizer Inc. and is seeking a turnaround,...
Stock market’s soft-landing rally faces CPI inflation test. Here’s what investors should do.
Middle East tensions, the port strike and the Fed’s interest-rate outlook puts inflation front and center again for the U.S....
Third-quarter earnings are upon us. So are worries of slower growth.
This summer, restaurants and many retailers who weren’t Walmart warned of a struggling consumer.
Trump and Harris say they want to cut taxes. Here’s why you should prepare for a tax hike.
Whoever wins November’s presidential election will be faced with an immediate need to negotiate with Congress over what income-tax rates...